Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer

References

• Becker M, Muller CB, De Bastiani MA, Klamt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol Histopathol 2014;29(1):21-31
   PubMed Web of Science ®Google Scholar
• Jadus MR, Natividad J, Mai A, et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012;2012:160724
   PubMed Web of Science ®Google Scholar
• Socola F, Scherfenberg N, Raez LE. Therapeutic vaccines in non-small cell lung cancer. Immunotargets Therapy 2013;2:115-24
   PubMedGoogle Scholar
• Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011;6(4):824-33
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011;17(16):5247-56
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24(29):4721-30
   PubMed Web of Science ®Google Scholar
• Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137(9):1337-42
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31(19):2396-403
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Douillard JY, Blumenschein GRJr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 2011;6(10):1763-73
   PubMed Web of Science ®Google Scholar
• Garcia B, Neninger E, Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;14(3). 840-6
   PubMed Web of Science ®Google Scholar
• Todeschini A, Hakomori SI. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 2008;1780(3):421-33
   PubMed Web of Science ®Google Scholar
• Handa K, Hakomori SI. Carbohydrate to carbohydrate interaction in development process and cancer progression. Glycoconj J 2012;29(8-9):627-37
   PubMed Web of Science ®Google Scholar
• Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs 2003;17(3):155-67
   PubMed Web of Science ®Google Scholar
• Blanco R, Rengifo E, Cedeno M, et al. Immunoreactivity of the 14F7 Mab raised against N-glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol 2011;2011:645641
   PubMedGoogle Scholar
• Hayashi N, Chiba H, Kuronuma K, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013;104(1):43-7
   PubMed Web of Science ®Google Scholar
• Scursoni AM, Galluzzo L, Camarero S, et al. Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011;2011:245181
   Google Scholar
• Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001;83(7):623-34
   PubMed Web of Science ®Google Scholar
• Irie A, Koyama S, Kozutsumi Y, et al. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 1998;273(25):15866-71
   PubMed Web of Science ®Google Scholar
• Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005;280(6):4228-37
   PubMed Web of Science ®Google Scholar
• Yin J, Hashimoto A, Izawa M, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 2006;66(6):2937-45
   PubMed Web of Science ®Google Scholar
• Zeng G, Gao L, Yu RK. Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed. Int J Cancer 2000;88(1):53-7
   PubMed Web of Science ®Google Scholar
• Bennaceur K, Popa I, Portoukalian J, et al. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 2006;18(6):879-86
   PubMed Web of Science ®Google Scholar
• Caldwell S, Heitger A, Shen W, et al. Mechanisms of ganglioside inhibition of APC function. J Immunol 2003;171(4):1676-83
   PubMed Web of Science ®Google Scholar
• Nicoll G, Avril T, Lock K, et al. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol 2003;33(6):1642-8
   PubMed Web of Science ®Google Scholar
• Hossain DM, Mohanty S, Ray P, et al. Tumor gangliosides and T cells: a deadly encounter. Front Biosci (Schol Ed) 2012;4:502-19
   PubMedGoogle Scholar
• Sorice M, Pavan A, Misasi R, et al. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand J Immunol 1995;41(2):148-56
   PubMed Web of Science ®Google Scholar
• de Leon J, Fernandez A, Mesa C, et al. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006;55(4):443-50
   PubMed Web of Science ®Google Scholar
• Casadesús AV, Fernandez-Marrero Y, Clavell M, et al. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. Glycoconj J 2013;30(7):687-99
   PubMed Web of Science ®Google Scholar
• Gabri MR, Otero LL, Gomez DE, Alonso DF. Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res 2009;28:146
   PubMed Web of Science ®Google Scholar
• Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6(6):357-66
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C(1-2):373-89
   PubMedGoogle Scholar
• Jerne NK. The generative grammar of the immune system. Science 1985;229(4718):1057-9
   PubMed Web of Science ®Google Scholar
• Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89(2):466-70
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Zabalegui N, Rodriguez-Calvillo M, et al. Anti-idiotype antibodies in cancer treatment. Oncogene 2007;26(25):3594-602
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Spendlove I, Watson NF, et al. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 2008;128(2):148-54
   PubMed Web of Science ®Google Scholar
• Chong G, Bhatnagar A, Cunningham D, et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 2006;17(3):437-42
   PubMed Web of Science ®Google Scholar
• Vazquez AM, Alfonso M, Lanne B, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995;14(6):551-6
   PubMedGoogle Scholar
• Neninger E, Diaz RM, Torre A, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007;6(2):145-50
   PubMed Web of Science ®Google Scholar
• Perez A, Lombardero J, Mateo C, et al. Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family. Hybridoma 2001;20(4):211-21
   PubMedGoogle Scholar
• Vazquez AM, Perez A, Hernandez AM, et al. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998;17(6):527-34
   PubMedGoogle Scholar
• Baskin JG, Ryan TM, Vakil M, et al. Thymus-dependent antiidiotype and anti-antiidiotype responses to a dinitrophenyl-specific monoclonal antibody. J Immunol 1990;145(1):202-8
   PubMed Web of Science ®Google Scholar
• Hernandez AM, Rodriguez M, Lopez-Requena A, et al. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 2005;210(1):11-21
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3(10):944-50
   PubMed Web of Science ®Google Scholar
• Rademaekers A, Kolsch E. Regulation of an anti-polysaccharide immune response in BALB/c mice through a tight T and B lymphocyte idiotypic connection. Eur J Immunol 1995;25(2):623-6
   PubMed Web of Science ®Google Scholar
• Rademaekers A, Specht C, Kolsch E. T-cell enforced invariance of the antibody repertoire in the immune response against a bacterial carbohydrate antigen. Scand J Immunol 2001;53(3):240-4
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med 2003;3(8):693-706
   PubMed Web of Science ®Google Scholar
• Diaz Y, Gonzalez A, Lopez A, et al. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009;58(7):1117-28
   PubMed Web of Science ®Google Scholar
• Vazquez AM, Gabri MR, Hernandez AM, et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000;7(4):751-6
   PubMed Web of Science ®Google Scholar
• Fuentes D, Avellanet J, Garcia A, et al. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010;120(2):379-89
   Google Scholar
• Machado YJ, Rabasa Y, Montesinos R, et al. Physicochemical and biological characterization of 1E10 anti-idiotype vaccine. BMC Biotechnol 2011;11:112
   PubMed Web of Science ®Google Scholar
• Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168(5):2523-9
   PubMed Web of Science ®Google Scholar
• Diaz A, Alfonso M, Alonso R, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003;107(2):80-9
   PubMed Web of Science ®Google Scholar
• Guthmann MD, Castro MA, Cinat G, et al. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006;29(2):215-23
   PubMed Web of Science ®Google Scholar
• Alfonso S, Diaz RM, Torre A, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007;6(12):1847-52
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Neninger E, et al. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 2007;3(1):8-13
   PubMed Web of Science ®Google Scholar
• Hernandez AM, Toledo D, Martinez D, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008;181(9):6625-34
   PubMed Web of Science ®Google Scholar
• Tjandra JJ, Ramadi L, McKenzie IF. Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 1990;68(6):367-76
   PubMedGoogle Scholar
• Mittelman A, Chen ZJ, Kageshita T, et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990;86(6):2136-44
   PubMed Web of Science ®Google Scholar
• Durrant LG, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 2012;167(2):206-15
   PubMed Web of Science ®Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette–Guerin. Clin Cancer Res 1999;5(6):1319-23
   PubMed Web of Science ®Google Scholar
• Yao TJ, Meyers M, Livingston PO, et al. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999;5(1):77-81
   PubMed Web of Science ®Google Scholar
• Bowes T, Wagner ER, Boffey J, et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain–Barre syndrome. Infect Immun 2002;70(9):5008-18
   PubMed Web of Science ®Google Scholar
• Chen ZC, Radic MZ, Galili U. Genes coding evolutionary novel anti-carbohydrate antibodies: studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice. Mol Immunol 2000;37(8):455-66
   PubMed Web of Science ®Google Scholar
• Hernandez AM, Rodriguez N, Gonzalez JE, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011;186(6):3735-44
   PubMed Web of Science ®Google Scholar
• Perez A, Mier ES, Vispo NS, et al. A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Mol Immunol 2002;39(1-2):103-12
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Roque-Navarro L, Lopez-Requena A, et al. Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology 2007;212(1):57-70
   PubMed Web of Science ®Google Scholar
• Cohen IR. Biomarkers, self-antigens and the immunological homunculus. J Autoimmun 2007;29(4):246-9
   PubMed Web of Science ®Google Scholar
• Watanabe T, Pukel CS, Takeyama H, et al. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 1982;156(6):1884-9
   PubMed Web of Science ®Google Scholar
• Tai T, Cahan LD, Tsuchida T, et al. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985;35(5):607-12
   PubMed Web of Science ®Google Scholar
• Ravindranath RM, Ravindranath MH, Graves MC. Augmentation of natural antiganglioside IgM antibodies in lower motor neuron disease (LMND) and role of CD5+ B cells. Cell Mol Life Sci 1997;53(9):750-8
   PubMed Web of Science ®Google Scholar
• Lardone RD, Alaniz ME, Irazoqui FJ, Nores GA. Unusual presence of anti-GM1 IgG-antibodies in a healthy individual, and their possible involvement in the origin of disease-associated anti-GM1 antibodies. J Neuroimmunol 2006;173(1-2):174-9
   PubMed Web of Science ®Google Scholar
• Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002;9(6):376-81
   PubMed Web of Science ®Google Scholar
• Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005;175(1):228-36
   PubMed Web of Science ®Google Scholar
• Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008;18(10):818-30
   PubMed Web of Science ®Google Scholar
• Rodriguez-Zhurbenko N, Martinez D, Blanco R, et al. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur J Immunol 2013;43(3):826-37
   PubMed Web of Science ®Google Scholar
• Alfonso S, Valdes-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab–alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20(14):3660-71
   PubMed Web of Science ®Google Scholar
• Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer. 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002;94(10):2766-92
   PubMed Web of Science ®Google Scholar
• Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 2004;100(1):6-11
   PubMed Web of Science ®Google Scholar
• Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Contr 2001;8(2 Suppl):1-25. quiz 27-8
   PubMedGoogle Scholar
• Gridelli C, Rossi A, Maione P. Challenges treating older non-small cell lung cancer patients. Ann Oncol 2008;19(7 Suppl):vii109-13
   PubMedGoogle Scholar
• US National Institute of Health. Immunotherapy with racotumomab in advanced lung cancer. http://clinicaltrials.gov/show/NCT01460472 [Accessed September 2014]
   Google Scholar
• Varela FJ, Coutinho A. Second generation immune networks. Immunol Today 1991;12(5):159-66
   PubMedGoogle Scholar